Related Experiment Video
Updated: Mar 20, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.5K
Factor X and its deficiency states
1Katharine Dormandy Haemophilia Center and Haemostasis Unit, Department of Haematology, Royal Free Hospital & School of Medicine, Pond Street, London NW3 2QG, UK.
Summary
Factor X, a key protein in blood clotting, plays a vital role in coagulation. Factor X deficiency, a rare inherited disorder, presents with variable bleeding tendencies and is treated with factor replacement therapy.
Area of Science:
- Biochemistry
- Hematology
- Genetics
Background:
- Factor X is a vitamin-K-dependent serine protease central to blood coagulation.
- It bridges the intrinsic and extrinsic pathways, forming the prothrombinase complex upon activation.
Purpose of the Study:
- To detail the role of Factor X in coagulation.
- To describe the genetic basis and inheritance patterns of Factor X deficiency.
- To outline current treatment strategies for Factor X deficiency.
Main Methods:
- Gene cloning and sequencing of Factor X.
- Analysis of Factor X gene structure and protein homology.
- Review of Factor X deficiency prevalence and clinical characteristics.
Main Results:
- The Factor X gene is located on chromosome 13, with exons encoding specific functional domains.
- Factor X exhibits homology with other vitamin-K-dependent clotting factors.
- Factor X deficiency is a rare autosomal recessive disorder with variable bleeding, affecting 1:500,000 homozygotes and ~1:500 heterozygotes.
Conclusions:
- Factor X is crucial for hemostasis, with its gene structure reflecting evolutionary relationships.
- Factor X deficiency requires careful management, balancing replacement therapy risks like thrombosis.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
01:24Disorders of Hemostasis
2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
15.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.0K
01:29Venous Thrombosis III: Interprofessional Care
459
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
459
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:09Coagulation
11.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
11.8K